MedPath

Fluticasone furoate

Generic Name
Fluticasone furoate
Brand Names
Arnuity Ellipta, Avamys, Breo Ellipta, Flonase Sensimist, Trelegy Ellipta, Veramyst
Drug Type
Small Molecule
Chemical Formula
C27H29F3O6S
CAS Number
397864-44-7
Unique Ingredient Identifier
JS86977WNV
Background

Fluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications. Fluticasone furoate was first approved in 2007.

Indication

Fluticasone furoate is indicated for once-daily maintenance (i.e. prophylactic) treatment of asthma in patients ≥5 years old. Fluticasone furoate is available in two combination medications - one in combination with vilanterol and one in combination with both vilanterol and umeclidinium- which are both indicated for the management of chronic obstructive pulmonary disease (COPD) and for the treatment of asthma in patients ≥18 years old for the vilanterol-umeclidinium-fluticasone product and ≥5 years old for the vilanterol-fluticasone product.

Fluticasone furoate is available over the counter as a nasal spray for the symptomatic treatment of hay fever and other upper respiratory allergies in patients ≥2 years old.

Associated Conditions
Asthma, Chronic Obstructive Pulmonary Disease (COPD), Perennial Allergy, Seasonal Allergies
Clinical Trials
Related News

Royalty Pharma Secures 99.9% Shareholder Approval for $1.1 Billion External Manager Acquisition

• Royalty Pharma shareholders have overwhelmingly approved the acquisition of its external manager, with 99.9% voting in favor at the company's 2025 Annual General Meeting. • The $1.1 billion transaction will transition Royalty Pharma from an external management model to an integrated corporate structure, generating projected cash savings exceeding $1.6 billion over ten years. • The internalization is expected to strengthen corporate governance, enhance transparency, and better align leadership with shareholder interests while ensuring management continuity.

Trump's Executive Order Delays Medicare Drug Price Negotiations, Sparking Industry and Policy Debate

• President Trump signed an executive order extending the exemption period for small-molecule drugs from Medicare price negotiations by four years, a move criticized by advocacy groups as favoring pharmaceutical industry interests. • The order aims to address what the administration calls the "pill penalty" - the current policy where small-molecule drugs (90% of medications) face negotiations after 9 years while biologics have longer exemption periods. • The Medicare Drug Price Negotiation Program, established under the Biden administration, had already achieved price reductions of 38-79% on 10 high-cost drugs with projected savings of $6 billion if applied in 2023.

FDA Approves EGRIFTA WR™: New Weekly Reconstitution Formulation for HIV-Associated Lipodystrophy

• Theratechnologies has received FDA approval for EGRIFTA WR™ (tesamorelin F8), a new formulation that requires weekly rather than daily reconstitution for treating excess visceral abdominal fat in adults with HIV and lipodystrophy. • The improved formulation requires less than half the administration volume of the current EGRIFTA SV® version, offering a more convenient patient experience while maintaining bioequivalence to the original tesamorelin formulation. • Recent data presented at CROI 2025 highlights that BMI alone is insufficient for assessing cardiovascular risk in HIV patients, emphasizing the importance of measuring visceral adipose tissue in this population.

GSK's Relvar Ellipta Demonstrates Superior Asthma Control in Landmark Real-World Study

• The Salford Lung Study shows patients using Relvar Ellipta had double the odds of achieving improved asthma control compared to standard care treatments. • The groundbreaking 52-week open-label trial involved 4,233 patients and was designed to reflect real-world clinical practice with minimal exclusion criteria. • Despite promising control outcomes, Relvar Ellipta carries boxed warnings for asthma-related death risk in children and adolescents, limiting its use in these populations.

CMS Completes Second Round of Medicare Drug Price Negotiation Agreements with 15 Manufacturers

• CMS has secured agreements with all manufacturers of the 15 drugs selected for the second round of Medicare Drug Price Negotiation Program, with negotiated prices to be finalized by November 2025 and implemented January 2027. • The selected drugs account for $40.7 billion in Medicare Part D expenditures (14% of gross spending) and affect approximately 5.3 million Medicare enrollees, following the first round which achieved price reductions of 38-79%. • The program's future remains uncertain under the Trump administration, with Republican leadership signaling potential repeal efforts despite the program's progress and pharmaceutical companies already adjusting their strategies.

Biogen Secures $250M from Royalty Pharma to Advance Lupus Antibody into Phase III Trials

• Biogen has entered into a strategic funding agreement with Royalty Pharma, securing $250 million over six quarters to advance litifilimab, a promising lupus treatment, into Phase III development. • The BDCA2-targeting monoclonal antibody litifilimab showed significant reduction in joint pain for systemic lupus erythematosus patients in Phase II trials, with Phase III data expected between 2026-2027. • The deal includes milestone payments and mid-single-digit royalties on worldwide sales, coming at a crucial time as Biogen restructures its pipeline and faces various business challenges.

Sana Biotechnology Achieves Breakthrough in Type 1 Diabetes Treatment Without Immunosuppression

Sana Biotechnology has reported promising early trial results for type 1 diabetes treatment using allogeneic pancreatic islet cell transplantation without the need for immunosuppression. This groundbreaking development represents the first human evidence of successfully overcoming both allogeneic and autoimmune rejection in type 1 diabetes treatment.

Verona Pharma's Ensifentrine Shows Promise in COPD and COVID-19 Trials

• Verona Pharma's ensifentrine significantly reduced COPD exacerbations by 42% in the ENHANCE-2 phase 3 trial, paving the way for regulatory filings. • A pilot study is underway to evaluate ensifentrine's efficacy in hospitalized COVID-19 patients, leveraging its bronchodilator and anti-inflammatory properties. • Ensifentrine, a dual PDE3/PDE4 inhibitor, has received FDA support for phase 3 development in COPD, with two ENHANCE trials planned. • The ENHANCE trials will assess ensifentrine's impact on lung function and COPD symptoms, potentially addressing unmet needs in patients uncontrolled by current therapies.

GSK's Nucala (Mepolizumab) Shows Promise in COPD Treatment, Regulatory Submissions Underway

• GSK's Nucala (mepolizumab) demonstrates a clinically meaningful reduction in moderate/severe exacerbations in COPD patients with an eosinophilic phenotype. • The MATINEE Phase III trial supports regulatory submissions for Nucala as an add-on maintenance treatment for COPD, potentially the first monthly biologic for this condition. • Regulatory reviews are underway in both the US (FDA) and China (CNMPA), with the US PDUFA date set for May 7, 2025. • Nucala, already approved for other IL-5 mediated conditions, could offer a targeted therapy for up to 40% of COPD patients with type 2 inflammation.

Dupixent Approved for COPD: A New Era in Targeted Therapy

• The FDA has approved Dupixent (dupilumab) for COPD, marking the first targeted therapy addressing the IL-4 and IL-13 pathways linked to type 2 inflammation. • Clinical trials demonstrated Dupixent reduced moderate-to-severe COPD exacerbations by 30% over 52 weeks, with significant improvements in lung function. • COPD affects approximately 44 million people in the 7MM, with the market expected to reach USD 16 billion in 2023 and grow at a CAGR of 5% by 2034. • Emerging therapies like itepekimab, benralizumab, tezepelumab and mepolizumab are in development, poised to further transform the COPD treatment landscape.

GSK Announces Q3 2024 Results: Specialty Medicines Drive Growth, Pipeline Strengthens

• GSK's Q3 2024 sales reached £8.0 billion, with a 2% CER increase, driven by strong performance in Specialty Medicines, offsetting lower Vaccines sales. • R&D progress includes EU approval for Arexvy in adults aged 50-59 and positive Phase III results for depemokimab in chronic rhinosinusitis with nasal polyps (CRSwNP). • The company confirms its 2024 guidance, projecting a 7-9% turnover growth and a 10-12% increase in core EPS, excluding COVID-19 solutions. • A Q3 2024 dividend of 15p per share has been declared, with expectations to declare a 60p per share dividend for the full year.

Verona Pharma's Ensifentrine (Ohtuvayre) Approved for COPD Maintenance Treatment

• Verona Pharma's Ensifentrine, marketed as Ohtuvayre, received FDA approval on June 26th for maintenance treatment of chronic obstructive pulmonary disease (COPD). • Ohtuvayre, a first-in-class dual PDE3 and PDE4 inhibitor, combines bronchodilator and anti-inflammatory properties into a single compound. • Verona Pharma is also developing Ensifentrine for other respiratory indications, including Non-Cystic Fibrosis Bronchiectasis (NCFBE), with a Phase 2 study initiating this quarter. • The initial list price for Ohtuvayre is $2,950 per month, with the company focusing on high-volume prescribing healthcare providers and securing Medicare and insurance coverage.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy